These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934 [TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials. Jenkins SG; Fisher AC; Peterson JA; Nicholson SC; Kaniga K Curr Med Res Opin; 2009 Dec; 25(12):3029-36. PubMed ID: 19849650 [TBL] [Abstract][Full Text] [Related]
6. Doripenem (Doribax)--a new parenteral carbapenem. Med Lett Drugs Ther; 2008 Jan; 50(1278):5-7. PubMed ID: 18219262 [No Abstract] [Full Text] [Related]
7. Doripenem: position in clinical practice. Dedhia HV; McKnight R Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791 [TBL] [Abstract][Full Text] [Related]
8. Doripenem: a new carbapenem in the treatment of nosocomial infection. Mandell L Clin Infect Dis; 2009 Aug; 49 Suppl 1():S1-3. PubMed ID: 19619016 [TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Kongnakorn T; Mwamburi M; Merchant S; Akhras K; Caro JJ; Nathwani D Curr Med Res Opin; 2010 Jan; 26(1):17-24. PubMed ID: 19895363 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravenous infusion of doripenem. Restrepo MI Clin Infect Dis; 2009 Aug; 49 Suppl 1():S17-27. PubMed ID: 19619018 [TBL] [Abstract][Full Text] [Related]
14. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Apisarnthanarak A; Mundy LM Int J Antimicrob Agents; 2012 Mar; 39(3):271-2. PubMed ID: 22236455 [No Abstract] [Full Text] [Related]
15. Clinical and economic consequences of ventilator-associated pneumonia. Amin A Clin Infect Dis; 2009 Aug; 49 Suppl 1():S36-43. PubMed ID: 19619020 [TBL] [Abstract][Full Text] [Related]
16. Stability of doripenem in vitro in representative infusion solutions and infusion bags. Psathas PA; Kuzmission A; Ikeda K; Yasuo S Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795 [TBL] [Abstract][Full Text] [Related]
17. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Joseph J; Rodvold KA Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158 [TBL] [Abstract][Full Text] [Related]
18. Doripenem: a new addition to the carbapenem class of antimicrobials. Schafer JJ; Goff DA; Mangino JE Recent Pat Antiinfect Drug Discov; 2009 Jan; 4(1):18-28. PubMed ID: 19149693 [TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555 [TBL] [Abstract][Full Text] [Related]